COFRASA / GENERAC - Factors Favouring Aortic Stenosis

Head :Messika-Zeitoun David, SERVICE DE CARDIOLOGIE DU PROFESSEUR VAHANIAN

Last update : 08/07/2014 | Version : 1 | ID : 60116

General

Identification

Detailed name	Factors Favouring Aortic Stenosis
Sign or acronym	COFRASA / GENERAC
CNIL registration number, number and date of CPP agreement, AFSSAPS (French Health Products Safety Agency) authorisation	Accord CNIL : 31/07/2006

General Aspects

Medical area	Cardiology
Others (details)	Aortic stenosis
Keywords	heart failure, aortic valve replacement, aortic valve, vascular atherosclerotic disease, Death, myocardial infarction, stroke, intima-media.

Scientific investigator(s) (Contact)

Name of the director	Messika-Zeitoun
Surname	David
Address	75018 PARIS
Email	david.messika-zeitoun@bch.aphp.fr
Unit	SERVICE DE CARDIOLOGIE DU PROFESSEUR VAHANIAN

Collaborations

Funding

Funding status	Public
Details	AP-HP, DRC

Governance of the database

Sponsor(s) or organisation(s) responsible	AP-HP
Organisation status	Public

Additional contact

Main features

Type of database

Type of database	Study databases
Study databases (details)	Case control study
Database recruitment is carried out as part of an interventional study	No
Additional information regarding sample selection.	Prospective Other bodies active in creating this cohort: CHU, CHG, independent physicians, multiple recruitment sources but centralised evaluation at Bichat Inclusion cut-off date: 01/01/2011

Database objective

Main objective	To determine factors favouring aortic stenosis progression and more specifically the effect of biological markers for inflammation, coagulation, platelet aggregation and matrix metalloproteinases. Secondary objectives: - To assess the relationship between the increase in AS and progression of vascular atherosclerosis; - To research genetic susceptibility factors associated with AS with candidate genes (fetuin-A, matrix-GLA protein, vitamin D receptor) and genomewide association studies; - To identify the relationships between genetic polymorphisms of fetuin-A, matrix-GLA protein, vitamin D receptor with 1) plasma levels for fetuin-A, MGP, vitamin D and parathyroid hormone, 2) haemodynamic severity stenosis and 3) the progression of AS.
Inclusion criteria	Patient group (aortic sentosis) - age >=18 years - pure (no or minimal aortic valve stenosis), isolated (no valve disease >= grade 2/4), "degenerative" aortic valve stenosis; - no known severe renal insufficiency (creatinine clearance < 30 ml/min); - Patients affiliated with a social security scheme. Control group: age >=18 years, no known first degree relative with aortic valve stenosis: no valve

	disease >= grade 2/4; - no known severe renal insufficiency (creatinine clearance < 30 ml/min); - - Patients affiliated with a social security scheme.
Population type	
Age	Adulthood (19 to 24 years) Adulthood (25 to 44 years) Adulthood (45 to 64 years) Elderly (65 to 79 years) Great age (80 years and more)
Population covered	Sick population
Gender	Male Woman
Geography area	Regional
French regions covered by the database	Île-de-France
Detail of the geography area	Île-de-France
Data collection	
Dates	
Date of first collection (YYYY or MM/YYYY)	11/2006
Date of last collection (YYYY or MM/YYYY)	01/2011
Size of the database	
Size of the database (number of individuals)	[1000-10 000[individuals
Details of the number of individuals	- 1000 patients présentant un rétrécissement aortique / cases - 1500 contrôles / controls
Data	
Database activity	Data collection completed
Type of data collected	Clinical data Declarative data Paraclinical data Biological data
Clinical data (detail)	Direct physical measures

	Medical registration
Declarative data (detail)	Face to face interview
Paraclinical data (detail)	Imaging: echocardiography, carotid ultrasound, ECG.
Biological data (detail)	Blood (+ aortic valve specimen for operated patients)
Presence of a biobank	Yes
Contents of biobank	Whole blood Serum Plasma DNA
Details of biobank content	Serum bank, plasma bank, DNA bank, tissue bank (aortic valve specimen for operated patients)
Health parameters studied	Health event/morbidity Health event/mortality Health care consumption and services Quality of life/health perception
Care consumption (detail)	Hospitalization Medical/paramedical consultation Medicines consumption
Procedures	
Data collection method	Interview: from a paper questionnaire with double data entry. Clinical examinations: handwritten with double data entry. Clinical examinations: handwritten with double data entry.
Participant monitoring	Yes
Details on monitoring of participants	2 years
Links to administrative sources	No
Promotion and access	
Promotion	
Link to the document	http://www.ncbi.nlm.nih.gov/pubmed/23768690
Link to the document	http://www.ncbi.nlm.nih.gov/pubmed/23349346
Link to the document	http://www.ncbi.nlm.nih.gov/pubmed/23329150

Access	
Terms of data access (charter for data provision, format of data, availability delay)	Data may be used by academic teams: open to ancillary projects and replication of genetic studies. Data may not be used by industrial teams.
Access to aggregated data	Access on specific project only
Access to individual data	Access on specific project only